ARA Avanti Rx Analytics

Dr. Mehrdad Barghian Ph.D., M.Phil., QPIC, C.Chem.

“The most important thing is to always be open to ideas, and to think outside the box without compromising product quality, safety, and regulatory requirements”

Dr. Barghian is the President and Chief Executive Officer of ARA – Avanti Rx Analytics Inc., located in Ontario, Canada where he leads a team of highly skilled scientist and regulatory professionals dedicated to conducting analytical quality control, R&D, QA, RA, extraction, and purification on cannabinoids.

Dr. Barghian leverages background in organic synthesis, analytical chemistry, terpene science, and long standing experience in pharmaceutical quality control, quality assurance and regulatory affairs.

Dr. Barghian is also researcher conducting clinical studies on effects of CBD and CBG on mammalian cancer in collaboration with University of Georgia, school of medicine, Georgia, USA. His earlier career as a pharmaceutical R&D and Quality Control leader included positions with Genpharm (now known as Mylan), Apotex, Ciba Vision (now known as Alcon), and Aventis Pasteur (now known as Sanofi Pasteur).

Dr. Barghian earned his M.Phil. and Ph.D. in organic synthesis and analytical Chemistry from University of Cardiff, Wales, United Kingdom, and completed his CRC (Cancer Research Campaign) Post-doctoral research at the Queen Mary Westfield College, University of London, England.

Dr. Barghian is the president of the International Pharmaceutical Academy (IPA) and lectures throughout the world on numerous GMP compliance, validation, and analytical testing related matters.

Mr. Andrei Ponomarev, Former Health Canada, Senior Investigator

Mr. Ponomarev is a former Health Protection Branch (HPB) - Health Canada Senior GMP Drug Specialist/Compliance Investigator with over 20 years of service with the Health Canada.

After a 40-year career in the pharmaceutical industry Mr. Ponomarev is now a Senior Associate with Lachman Consultants, a world renowned compliance and regulatory affairs consulting firm based in USA and a senior board member of ARA – Avanti Rx Analytics Inc.

Prior to Lachman, Mr. Ponomarev held number of progressive senior positions where he delivered the strategic guidance and direction toward implementation of effective solutions for; quality systems, conducting pre-approval inspections, drug submissions, and commercialization.

In the past Mr. Ponomarev had held senior Quality and Compliance positions in multi-national pharmaceutical and biotech organizations such as; Aventis Pasture, Novartis Pharmaceuticals, Genpharm, and KGA Merck.

Additionally, he is highly skilled in remediation planning and implementation. Mr. Ponomarev’s expertise in quality systems design, enhancement, and implementation strengthens corporate total quality tenets to achieve company goals of compliance and profitability.

Dr. Babak Baban Ph.D., MBA, MPH

Dr. Babak Baban is an Associate Professor of Immunology at Departments of Oral Biology, Dental College of Georgia, Departments of Neurology and Department of Surgery, Medical College of Georgia, at Augusta University of Augusta GA in the USA. He received his Ph.D. from University of London in United Kingdom followed by completion of his postdoctoral fellowship in molecular immunology at the Medical College of Georgia (currently Augusta University) in the USA. With over 25 years of experience as a translational and applied immunologist, Dr. Baban’s research is focused on the mechanisms underlying the regulation of acquired and innate immune interactions; pathways by which those responses contribute to inflammatory and immunologic diseases, diabetes, cancer, transplantation disorders, cardiovascular and neurodegenerative diseases, determining therapeutic targets and disease control.

In addition to his academic position and directing immunology/microbiology course, Dr. Baban is a Fellow of American Heart Association. He is serving as the Editor-in-Chief, member of editorial board, and reviewer for several prestigious scientific journals as well as study sections of American Heart Association and Veteran affairs. He is the lead and corresponding author/contributing author of more than 70 peer review published articles, as well as several book chapters. He has presented his research in over 100 national and international scientific seminars and conferences. He is member of several prestigious scientific associations such as American Association of Immunology (AAI), American Heart Association (AHA), American Association for Cancer Research (AACR), American Dental Association (ADA) and American Association of Bioanalysis (AAB). In addition, Dr. Baban is mentoring and teaching at different level of pre-doctoral as well as graduate and post-graduate students and residents.

Further, Dr. Baban is an internationally recognized scientist. He is member of European Predictive, Protective, and Personalized Medicine Association (EPMA) as well as the organizing member of World Congress on Predictive, Protective, and Personalized Medicine. He is serving as a reviewer on multinational funding agencies for scientific research. 

Further, Dr. Baban earned his Master of Business Administration (MBA) from Augusta State University in 2008 and his Master of Public Health (MPH) from Augusta University in 2015.

Since 2014, Dr. Baban and his team in collaboration with other investigations has directed an extensive research project evaluating the potential therapeutic effects of medical cannabinoids in the treatment of inflammatory diseases, specifically cardiac and renal ischemic injury as well as cancer. Part of the preliminary findings of these studies were presented at Annual meeting of American Association for Cancer Research (AACR) (Determining Autophagic Activity Following Cannabidiol Treatment of Melanoma: A Potential New and Novel Treatment, AACR Annual Meeting 2016, April 16-20 in New Orleans, Louisiana). Another part of initial studies have been accepted to be presented at Annual meeting of American Public Health Association later this year in Denver Co (Cannabinoid in the Management of Melanoma: The Impact on Public Health" APHA 2016 Annual Meeting & Expo, Oct. 29 - Nov. 2, 2016, Denver, CO).

Dr. Jagan Payidiparty Ph.D., M.Phil., M.Sc.

Dr. Jagan is a highly accomplished pharmaceutical professional with over twenty years of experience in the area of pharmaceutical Quality Control, Quality Assurance, Research and Development (Analytical & Formulations), and Regulatory Affairs.

He joined ARA – Avanti Rx Analytics Inc. in March 2016 to build and lead a team of technical professionals and scientists. As the QA Compliance manager, he is responsible for overall internal Quality system, including; Training, Documentation, Compliance, Product and Process Development.

Prior to joining ARA, Dr. Jagan worked in various successful Pharmaceutical companies like Purine Pharma (USA), Teva Canada, Kanti Labs, and Pragati Chemical Industries. Some of his roles are Chief Scientific Officer, Manager, Supervisor, Team Leader, Scientist etc. Dr. Jagan has successfully led teams of scientists and technical professionals in Quality Control, Quality Assurance, Compliance, Research (Analytical & Formulations), Regulatory Affairs and commercial manufacturing of new or improved OTC and prescription liquid oral products.

He received his M.Phil. and Ph.D. in Chemistry from Mangalore University, India and pursued his post-doctoral research in Protein Chemistry by Electrospray Ionization Mass Spectroscopy from University of Western Ontario, London, Canada.

Additionally, Dr. Jagan was an Assistant Professor of Organic Chemistry at Andhra University of SVKP & Dr. KSR College, India from 1993 – 2000. He guided 46 post graduate scholars for their dissertations on Natural Products, Organic Reaction Mechanisms, Pharmaceutical Formulations and Analytical Chemistry. He is an examiner and reviewing several Ph.D. Thesis.

He has to his credit 23 publications in various peer reviewed journals. He is an Editorial Board Member for Journal of Analytical and Pharmaceutical Research, Oklahoma, USA.